ArticleBMC infectious diseases2026
Chronic blood-borne viral hepatitis in a tertiary hospital in Al-Baha, Saudi Arabia: epidemiology, liver enzyme correlations, and treatment outcomes.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Al-Baha viral hepatitis in clinical settings has not been adequately investigated. This study examined chronic HBV and HCV infections and their treatment outcomes among patients at King Fahd Hospital in Al-Baha.
methodsPatients records were retrieved anonymously for clinical, demographic, virological and biochemical data from January 2019 to December 2022.
resultsOf 148 patients (mean age was 49.6 ± 13.2; 56.8% males) 80.4% had HBV, 18.2% had HCV while 1.4% had dual infection. HBV viral loads correlated with ALT levels (r = 0.317, p = 0.001) while HCV viral loads did not. (r = 0.246, p = 0.23). Among the 148 cases, 144 were clinically classified as chronic HBV infections (n = 117), chronic HCV infections (n = 25), acute HCV infection (n = 1). The remaining cases were unclassified HCV infections (n = 4) or dual HBV/HCV infection (n = 1). Cirrhosis was observed in 6% of HBV cases and 18.5% of HCV cases. Viral load suppression with ALT levels either maintained at baseline or normalized in most cases occurred in 93.3% of HBV patients (n = 15) treated with tenofovir alafenamide and in all those (n = 8) treated with entecavir with generally unchanging ALT levels. All HCV patients (n = 16) achieved viral clearance after 12 weeks treatment course; sofosbuvir–daclatasvir (n = 14) was highly effective though 2 showed elevated post-treatment ALT.
conclusionsChronic HBV and HCV infections remain clinical challenge in Al-Baha. Current antivirals showed strong efficacy. Cirrhosis and post- treatment liver abnormalities underscores the need for continuing monitoring, improved prevention and broadened hepatitis health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.